CEACAM5 and neoplasm: Baseline tumor marker levels differed between groups, with lower median CEA (32.0 vs. 77.0 ng/mL, p < 0.001) and CA19-9 levels (25.0 vs. 38.5 U/mL, p = 0.047) in the metastasectomy cohort.